{
    "nct_id": "NCT03337451",
    "official_title": "Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)",
    "inclusion_criteria": "* Completion of the OPN-305-106 study\n* Principal Investigator adjudicated efficacy response defined as either transfusion independence\", \"stable disease\", \"minor HI-E response\" or \"major HI-E response\" and in the opinion of the Principal Investigator the patient may benefit from continued treatment with OPN-305 monotherapy or combination treatment with azacitidine.\n* Provide written informed consent for the follow up protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Refusal to provide written informed consent\n* Withdrawal from the OPN-305-106 study prior to the final EOT visit\n* Plan to be included into another interventional investigational study.\n* Progression of disease",
    "miscellaneous_criteria": ""
}